Pharvaris NV
PHVS28.380USD
+0.660+2.38%
Close 11/28, 13:00（ET）Quotes delayed by 15 min
1.84BMarket Cap
LossP/E TTM
More Details of Pharvaris NV Company
Pharvaris BV is a Switzerland-based clinical-stage company. The activity of the Company focuses on producing oral bradykinin B2-receptor antagonists and is advancing new alternatives to injected therapies for all sub-types of hereditary angioedema (HAE).
Pharvaris NV Info
Ticker SymbolPHVS
Company namePharvaris NV
IPO dateFeb 05, 2021
CEOMr. Berndt Modig, CPA
Number of employees- -
Security typeOrdinary Share
Fiscal year-endFeb 05
AddressEmmy Noetherweg 2
CityLEIDEN
Stock exchangeNASDAQ Global Select Consolidated
CountryNetherlands
Postal code2333 BK
Phone31712036410
Websitehttps://pharvaris.com/
Ticker SymbolPHVS
IPO dateFeb 05, 2021
CEOMr. Berndt Modig, CPA
Company Executives of Pharvaris NV
Name
Name/Position
Position
Shareholding
Change
Dr. David P. Meeker ,M.D.
Dr. David P. Meeker ,M.D.
Non-Executive Director
Non-Executive Director
102.82K
-15.53%
Ms. Viviane Monges
Ms. Viviane Monges
Non-Executive Director
Non-Executive Director
54.91K
+73.10%
Ms. Anna Nijdam
Ms. Anna Nijdam
Head of Finance, Principal Accounting Officer
Head of Finance, Principal Accounting Officer
50.54K
+0.63%
Dr. Elisabeth Bjork, M.D., Ph.D.
Dr. Elisabeth Bjork, M.D., Ph.D.
Non-Executive Director
Non-Executive Director
50.53K
+128.70%
Mr. David W. Nassif, J.D.
Mr. David W. Nassif, J.D.
Chief Financial Officer
Chief Financial Officer
800.00
--
Dr. Jochen Knolle, Ph.D.
Dr. Jochen Knolle, Ph.D.
Co-Founder, Chief Operating Officer, Chief Scientific Officer
Co-Founder, Chief Operating Officer, Chief Scientific Officer
--
--
Dr. Peng Lu, M.D., Ph.D.
Dr. Peng Lu, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Anne Marie De Jonge Schuermans, Ph.D.
Dr. Anne Marie De Jonge Schuermans, Ph.D.
Non-Executive Director
Non-Executive Director
--
--
Mr. Berndt Modig, CPA
Mr. Berndt Modig, CPA
Chief Executive Officer, Co-Founder, Executive Director
Chief Executive Officer, Co-Founder, Executive Director
--
--
Dr. Morgan Conn, Ph.D.
Dr. Morgan Conn, Ph.D.
Chief Business Officer
Chief Business Officer
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. David P. Meeker ,M.D.
Dr. David P. Meeker ,M.D.
Non-Executive Director
Non-Executive Director
102.82K
-15.53%
Ms. Viviane Monges
Ms. Viviane Monges
Non-Executive Director
Non-Executive Director
54.91K
+73.10%
Ms. Anna Nijdam
Ms. Anna Nijdam
Head of Finance, Principal Accounting Officer
Head of Finance, Principal Accounting Officer
50.54K
+0.63%
Dr. Elisabeth Bjork, M.D., Ph.D.
Dr. Elisabeth Bjork, M.D., Ph.D.
Non-Executive Director
Non-Executive Director
50.53K
+128.70%
Mr. David W. Nassif, J.D.
Mr. David W. Nassif, J.D.
Chief Financial Officer
Chief Financial Officer
800.00
--
Dr. Jochen Knolle, Ph.D.
Dr. Jochen Knolle, Ph.D.
Co-Founder, Chief Operating Officer, Chief Scientific Officer
Co-Founder, Chief Operating Officer, Chief Scientific Officer
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Mon, Nov 17
Updated: Mon, Nov 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
General Atlantic LLC
12.54%
Fidelity Management & Research Company LLC
9.99%
Foresite Capital Management, LLC
7.46%
VenBio Partners LLC
7.24%
Viking Global Investors LP
5.70%
Other
57.07%
Shareholders
Shareholders
Proportion
General Atlantic LLC
12.54%
Fidelity Management & Research Company LLC
9.99%
Foresite Capital Management, LLC
7.46%
VenBio Partners LLC
7.24%
Viking Global Investors LP
5.70%
Other
57.07%
Shareholder Types
Shareholders
Proportion
Private Equity
33.13%
Hedge Fund
22.83%
Investment Advisor
18.03%
Venture Capital
11.99%
Investment Advisor/Hedge Fund
9.82%
Individual Investor
5.32%
Research Firm
0.17%
Bank and Trust
0.07%
Pension Fund
0.05%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
118
49.64M
77.50%
-950.63K
2025Q2
125
52.21M
81.51%
-1.38M
2025Q1
125
53.89M
99.06%
+200.61K
2024Q4
123
53.45M
98.98%
+218.03K
2024Q3
114
53.86M
99.73%
+1.03M
2024Q2
83
52.08M
96.43%
-141.66K
2024Q1
76
49.63M
98.30%
-831.88K
2023Q4
69
47.76M
94.74%
+8.60M
2023Q3
54
36.05M
91.51%
-2.92M
2023Q2
53
35.78M
91.11%
+3.65M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
General Atlantic LLC
7.53M
11.76%
--
--
Jun 30, 2025
Fidelity Management & Research Company LLC
5.42M
8.47%
+27.02K
+0.50%
Jun 30, 2025
Foresite Capital Management, LLC
4.41M
6.89%
--
--
Jun 30, 2025
VenBio Partners LLC
4.29M
6.7%
--
--
Jun 30, 2025
Viking Global Investors LP
3.65M
5.7%
--
--
Jun 30, 2025
EQT Life Sciences
3.56M
5.55%
--
--
Apr 01, 2025
Bain Capital Life Sciences Investors, LLC
3.30M
5.16%
--
--
Jun 30, 2025
Deerfield Management Company, L.P.
2.02M
3.15%
--
--
Jun 30, 2025
Commodore Capital LP
1.91M
2.98%
--
--
Jun 30, 2025
View more
Related ETFs
Updated: Thu, Nov 6
Updated: Thu, Nov 6
Name
Proportion
Virtus LifeSci Biotech Clinical Trials ETF
1.05%
ALPS Medical Breakthroughs ETF
0.95%
iShares MSCI Netherlands ETF
0.27%
SPDR S&P International Small Cap ETF
0.08%
iShares MSCI Europe Small-Cap ETF
0.04%
iShares MSCI EAFE Small-Cap ETF
0.02%
Fidelity Nasdaq Composite Index ETF
0.01%
Xtrackers MSCI Eurozone Hedged Eqty ETF
0.01%
Avantis International Small Cap Equity ETF
0%
First Trust IPOX Europe Equity Opportunities ETF
0%
View more
Virtus LifeSci Biotech Clinical Trials ETF
Proportion1.05%
ALPS Medical Breakthroughs ETF
Proportion0.95%
iShares MSCI Netherlands ETF
Proportion0.27%
SPDR S&P International Small Cap ETF
Proportion0.08%
iShares MSCI Europe Small-Cap ETF
Proportion0.04%
iShares MSCI EAFE Small-Cap ETF
Proportion0.02%
Fidelity Nasdaq Composite Index ETF
Proportion0.01%
Xtrackers MSCI Eurozone Hedged Eqty ETF
Proportion0.01%
Avantis International Small Cap Equity ETF
Proportion0%
First Trust IPOX Europe Equity Opportunities ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Pharvaris NV?
The top five shareholders of Pharvaris NV are:
General Atlantic LLC holds 7.53M shares, accounting for 11.76% of the total shares.
Fidelity Management & Research Company LLC holds 5.42M shares, accounting for 8.47% of the total shares.
Foresite Capital Management, LLC holds 4.41M shares, accounting for 6.89% of the total shares.
VenBio Partners LLC holds 4.29M shares, accounting for 6.70% of the total shares.
Viking Global Investors LP holds 3.65M shares, accounting for 5.70% of the total shares.
General Atlantic LLC holds 7.53M shares, accounting for 11.76% of the total shares.
Fidelity Management & Research Company LLC holds 5.42M shares, accounting for 8.47% of the total shares.
Foresite Capital Management, LLC holds 4.41M shares, accounting for 6.89% of the total shares.
VenBio Partners LLC holds 4.29M shares, accounting for 6.70% of the total shares.
Viking Global Investors LP holds 3.65M shares, accounting for 5.70% of the total shares.
What are the top three shareholder types of Pharvaris NV?
The top three shareholder types of Pharvaris NV are:
General Atlantic LLC
Fidelity Management & Research Company LLC
Foresite Capital Management, LLC
General Atlantic LLC
Fidelity Management & Research Company LLC
Foresite Capital Management, LLC
How many institutions hold shares of Pharvaris NV (PHVS)?
As of 2025Q3, 118 institutions hold shares of Pharvaris NV, with a combined market value of approximately 49.64M, accounting for 77.50% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -4.01%.
What is the biggest source of revenue for Pharvaris NV?
In --, the -- business generated the highest revenue for Pharvaris NV, amounting to -- and accounting for --% of total revenue.
